$0.33
0.00%
Nasdaq, Tue, May 20 2025
ISIN
US01671P1003
Symbol
ALLK
Sector
Industry

Allakos, Inc. Stock price

$0.33
+0.00 1.26% 1M
-0.61 64.96% 6M
-0.88 72.80% YTD
-1.10 76.99% 1Y
-2.67 89.03% 3Y
-76.98 99.57% 5Y
-30.92 98.95% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.00%
ISIN
US01671P1003
Symbol
ALLK
Sector
Industry

Key metrics

Market capitalization $29.74m
Enterprise Value $-25.50m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.28
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-99.75m
Free Cash Flow (TTM) Free Cash Flow $-89.69m
Cash position $55.24m
EPS (TTM) EPS $-0.79
Short interest 0.51%
Show more

Is Allakos, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Allakos, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Allakos, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Allakos, Inc.:

Hold
100%

Financial data from Allakos, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 15 15
147% 147%
-
-15 -15
147% 147%
-
- Selling and Administrative Expenses 26 26
28% 28%
-
- Research and Development Expense 44 44
70% 70%
-
-85 -85
55% 55%
-
- Depreciation and Amortization 15 15
147% 147%
-
EBIT (Operating Income) EBIT -100 -100
49% 49%
-
Net Profit -71 -71
67% 67%
-

In millions USD.

Don't miss a Thing! We will send you all news about Allakos, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Allakos, Inc. Stock News

Neutral
Business Wire
about 2 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Allakos Inc. (NASDAQ: ALLK) to Concentra Biosciences, LLC for $0.33 in cash per share is fair to Allakos shareholders. Halper Sadeh encourages Allakos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-00...
Neutral
Business Wire
about 2 months ago
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer tra...
Neutral
GlobeNewsWire
about 2 months ago
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC ( “Concentra”) will acquire Allakos for $0....
More Allakos, Inc. News

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.

Head office United States
CEO Robert Alexander
Employees 61
Founded 2012
Website www.allakos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today